TriangleNCT02399371 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 years
What was measured
Time from detection of response to disease progression or death, estimated by Kaplan-Meier with 95% confidence interval using the Brookmeyer-Crowley method.
Analysis population: Responding patients (CR or PR).
Groups in this outcome
Treatment (Pembrolizumab)
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab. Pembrolizumab: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacogenomic Study: Correlative studies
| Group | Source count |
|---|---|
| Treatment (Pembrolizumab) | 14 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Pembrolizumab) | 11.7 | Not reported | 2.1 | NA | NA = Upper confidence limit cannot be estimated due to insufficient number of participants with events. |
Complete source fields
- classes
- categories
- measurements
- comment
- NA = Upper confidence limit cannot be estimated due to insufficient number of participants with events.
- group Id
- OG000
- lower Limit
- 2.1
- upper Limit
- NA
- value
- 11.7
- denoms
- counts
- group Id
- OG000
- value
- 14
- units
- Participants
- description
- Time from detection of response to disease progression or death, estimated by Kaplan-Meier with 95% confidence interval using the Brookmeyer-Crowley method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab. Pembrolizumab: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacogenomic Study: Correlative studies
- id
- OG000
- title
- Treatment (Pembrolizumab)
- param Type
- MEDIAN
- population Description
- Responding patients (CR or PR).
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Duration of Response
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice